Cargando…

Apoptotic Efficacy of Etomoxir in Human Acute Myeloid Leukemia Cells. Cooperation with Arsenic Trioxide and Glycolytic Inhibitors, and Regulation by Oxidative Stress and Protein Kinase Activities

Fatty acid synthesis and oxidation are frequently exacerbated in leukemia cells, and may therefore represent a target for therapeutic intervention. In this work we analyzed the apoptotic and chemo-sensitizing action of the fatty acid oxidation inhibitor etomoxir in human acute myeloid leukemia cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Estañ, María Cristina, Calviño, Eva, Calvo, Susana, Guillén-Guío, Beatriz, Boyano-Adánez, María del Carmen, de Blas, Elena, Rial, Eduardo, Aller, Patricio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266683/
https://www.ncbi.nlm.nih.gov/pubmed/25506699
http://dx.doi.org/10.1371/journal.pone.0115250
_version_ 1782349048452218880
author Estañ, María Cristina
Calviño, Eva
Calvo, Susana
Guillén-Guío, Beatriz
Boyano-Adánez, María del Carmen
de Blas, Elena
Rial, Eduardo
Aller, Patricio
author_facet Estañ, María Cristina
Calviño, Eva
Calvo, Susana
Guillén-Guío, Beatriz
Boyano-Adánez, María del Carmen
de Blas, Elena
Rial, Eduardo
Aller, Patricio
author_sort Estañ, María Cristina
collection PubMed
description Fatty acid synthesis and oxidation are frequently exacerbated in leukemia cells, and may therefore represent a target for therapeutic intervention. In this work we analyzed the apoptotic and chemo-sensitizing action of the fatty acid oxidation inhibitor etomoxir in human acute myeloid leukemia cells. Etomoxir caused negligible lethality at concentrations up to 100 µM, but efficaciously cooperated to cause apoptosis with the anti-leukemic agent arsenic trioxide (ATO, Trisenox), and with lower efficacy with other anti-tumour drugs (etoposide, cisplatin), in HL60 cells. Etomoxir-ATO cooperation was also observed in NB4 human acute promyelocytic cells, but not in normal (non-tumour) mitogen-stimulated human peripheral blood lymphocytes. Biochemical determinations in HL60 cells indicated that etomoxir (25–200 µM) dose-dependently inhibited mitochondrial respiration while slightly stimulating glycolysis, and only caused marginal alterations in total ATP content and adenine nucleotide pool distribution. In addition, etomoxir caused oxidative stress (increase in intracellular reactive oxygen species accumulation, decrease in reduced glutathione content), as well as pro-apoptotic LKB-1/AMPK pathway activation, all of which may in part explain the chemo-sensitizing capacity of the drug. Etomoxir also cooperated with glycolytic inhibitors (2-deoxy-D-glucose, lonidamine) to induce apoptosis in HL60 cells, but not in NB4 cells. The combined etomoxir plus 2-deoxy-D-glucose treatment did not increase oxidative stress, caused moderate decrease in net ATP content, increased the AMP/ATP ratio with concomitant drop in energy charge, and caused defensive Akt and ERK kinase activation. Apoptosis generation by etomoxir plus 2-deoxy-D-glucose was further increased by co-incubation with ATO, which is apparently explained by the capacity of ATO to attenuate Akt and ERK activation. In summary, co-treatment with etomoxir may represent an interesting strategy to increase the apoptotic efficacy of ATO and (with some limitations) 2-deoxy-D-glucose which, although clinically important anti-tumour agents, exhibit low efficacy in monotherapy.
format Online
Article
Text
id pubmed-4266683
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-42666832014-12-26 Apoptotic Efficacy of Etomoxir in Human Acute Myeloid Leukemia Cells. Cooperation with Arsenic Trioxide and Glycolytic Inhibitors, and Regulation by Oxidative Stress and Protein Kinase Activities Estañ, María Cristina Calviño, Eva Calvo, Susana Guillén-Guío, Beatriz Boyano-Adánez, María del Carmen de Blas, Elena Rial, Eduardo Aller, Patricio PLoS One Research Article Fatty acid synthesis and oxidation are frequently exacerbated in leukemia cells, and may therefore represent a target for therapeutic intervention. In this work we analyzed the apoptotic and chemo-sensitizing action of the fatty acid oxidation inhibitor etomoxir in human acute myeloid leukemia cells. Etomoxir caused negligible lethality at concentrations up to 100 µM, but efficaciously cooperated to cause apoptosis with the anti-leukemic agent arsenic trioxide (ATO, Trisenox), and with lower efficacy with other anti-tumour drugs (etoposide, cisplatin), in HL60 cells. Etomoxir-ATO cooperation was also observed in NB4 human acute promyelocytic cells, but not in normal (non-tumour) mitogen-stimulated human peripheral blood lymphocytes. Biochemical determinations in HL60 cells indicated that etomoxir (25–200 µM) dose-dependently inhibited mitochondrial respiration while slightly stimulating glycolysis, and only caused marginal alterations in total ATP content and adenine nucleotide pool distribution. In addition, etomoxir caused oxidative stress (increase in intracellular reactive oxygen species accumulation, decrease in reduced glutathione content), as well as pro-apoptotic LKB-1/AMPK pathway activation, all of which may in part explain the chemo-sensitizing capacity of the drug. Etomoxir also cooperated with glycolytic inhibitors (2-deoxy-D-glucose, lonidamine) to induce apoptosis in HL60 cells, but not in NB4 cells. The combined etomoxir plus 2-deoxy-D-glucose treatment did not increase oxidative stress, caused moderate decrease in net ATP content, increased the AMP/ATP ratio with concomitant drop in energy charge, and caused defensive Akt and ERK kinase activation. Apoptosis generation by etomoxir plus 2-deoxy-D-glucose was further increased by co-incubation with ATO, which is apparently explained by the capacity of ATO to attenuate Akt and ERK activation. In summary, co-treatment with etomoxir may represent an interesting strategy to increase the apoptotic efficacy of ATO and (with some limitations) 2-deoxy-D-glucose which, although clinically important anti-tumour agents, exhibit low efficacy in monotherapy. Public Library of Science 2014-12-15 /pmc/articles/PMC4266683/ /pubmed/25506699 http://dx.doi.org/10.1371/journal.pone.0115250 Text en © 2014 Estañ et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Estañ, María Cristina
Calviño, Eva
Calvo, Susana
Guillén-Guío, Beatriz
Boyano-Adánez, María del Carmen
de Blas, Elena
Rial, Eduardo
Aller, Patricio
Apoptotic Efficacy of Etomoxir in Human Acute Myeloid Leukemia Cells. Cooperation with Arsenic Trioxide and Glycolytic Inhibitors, and Regulation by Oxidative Stress and Protein Kinase Activities
title Apoptotic Efficacy of Etomoxir in Human Acute Myeloid Leukemia Cells. Cooperation with Arsenic Trioxide and Glycolytic Inhibitors, and Regulation by Oxidative Stress and Protein Kinase Activities
title_full Apoptotic Efficacy of Etomoxir in Human Acute Myeloid Leukemia Cells. Cooperation with Arsenic Trioxide and Glycolytic Inhibitors, and Regulation by Oxidative Stress and Protein Kinase Activities
title_fullStr Apoptotic Efficacy of Etomoxir in Human Acute Myeloid Leukemia Cells. Cooperation with Arsenic Trioxide and Glycolytic Inhibitors, and Regulation by Oxidative Stress and Protein Kinase Activities
title_full_unstemmed Apoptotic Efficacy of Etomoxir in Human Acute Myeloid Leukemia Cells. Cooperation with Arsenic Trioxide and Glycolytic Inhibitors, and Regulation by Oxidative Stress and Protein Kinase Activities
title_short Apoptotic Efficacy of Etomoxir in Human Acute Myeloid Leukemia Cells. Cooperation with Arsenic Trioxide and Glycolytic Inhibitors, and Regulation by Oxidative Stress and Protein Kinase Activities
title_sort apoptotic efficacy of etomoxir in human acute myeloid leukemia cells. cooperation with arsenic trioxide and glycolytic inhibitors, and regulation by oxidative stress and protein kinase activities
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266683/
https://www.ncbi.nlm.nih.gov/pubmed/25506699
http://dx.doi.org/10.1371/journal.pone.0115250
work_keys_str_mv AT estanmariacristina apoptoticefficacyofetomoxirinhumanacutemyeloidleukemiacellscooperationwitharsenictrioxideandglycolyticinhibitorsandregulationbyoxidativestressandproteinkinaseactivities
AT calvinoeva apoptoticefficacyofetomoxirinhumanacutemyeloidleukemiacellscooperationwitharsenictrioxideandglycolyticinhibitorsandregulationbyoxidativestressandproteinkinaseactivities
AT calvosusana apoptoticefficacyofetomoxirinhumanacutemyeloidleukemiacellscooperationwitharsenictrioxideandglycolyticinhibitorsandregulationbyoxidativestressandproteinkinaseactivities
AT guillenguiobeatriz apoptoticefficacyofetomoxirinhumanacutemyeloidleukemiacellscooperationwitharsenictrioxideandglycolyticinhibitorsandregulationbyoxidativestressandproteinkinaseactivities
AT boyanoadanezmariadelcarmen apoptoticefficacyofetomoxirinhumanacutemyeloidleukemiacellscooperationwitharsenictrioxideandglycolyticinhibitorsandregulationbyoxidativestressandproteinkinaseactivities
AT deblaselena apoptoticefficacyofetomoxirinhumanacutemyeloidleukemiacellscooperationwitharsenictrioxideandglycolyticinhibitorsandregulationbyoxidativestressandproteinkinaseactivities
AT rialeduardo apoptoticefficacyofetomoxirinhumanacutemyeloidleukemiacellscooperationwitharsenictrioxideandglycolyticinhibitorsandregulationbyoxidativestressandproteinkinaseactivities
AT allerpatricio apoptoticefficacyofetomoxirinhumanacutemyeloidleukemiacellscooperationwitharsenictrioxideandglycolyticinhibitorsandregulationbyoxidativestressandproteinkinaseactivities